Management of osteoporosis in patients with gastrointestinal diseases

European Journal of Gastroenterology and Hepatology

Volumn 15, Issue 8, 2003, Pages 869-876

  Von Tirpitz, Christian ^a   Reinshagen, Max ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Bisphosphonate; Coeliac disease; Crohn's disease; Osteoporosis; Sodium fluoride

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CORTICOSTEROID; ESTROGEN; ETIDRONIC ACID; FLUORIDE SODIUM; GLUCOCORTICOID; IBANDRONIC ACID; OSTEOPROTEGERIN; PANCREAS ENZYME; PARATHYROID HORMONE[1-34]; PLACEBO; PROGESTERONE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; VITAMIN D; ZOLEDRONIC ACID;

AGING; BONE DISEASE; CARDIOVASCULAR DISEASE; CELIAC DISEASE; CHRONIC PANCREATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID INDUCED OSTEOPOROSIS; CROHN DISEASE; ENDOMETRIUM CANCER; ENTERITIS; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; EXERCISE; FRACTURE; GASTROINTESTINAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; OSTEOPOROSIS; PANCREAS INSUFFICIENCY; POSTGASTRECTOMY SYNDROME; POSTMENOPAUSE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT OUTCOME; VITAMIN INTAKE;

BONE AND BONES; CALCITONIN; CALCIUM; CELIAC DISEASE; DIETARY SUPPLEMENTS; DIPHOSPHONATES; FEMALE; GASTRECTOMY; GASTROINTESTINAL DISEASES; HORMONE REPLACEMENT THERAPY; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; OSTEOPOROSIS; SODIUM FLUORIDE; VITAMIN D;

EID: 0041314015     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200308000-00006     Document Type: Review

References (76)

1. Diamond T, Stiel D, Posen S. Osteoporosis in hemochromatosis: iron excess, gonadal deficiency, or other factors? Ann Intern Med 1989; 110:430-436.
2. Klaus J, Brueckel J, Steinkamp M, Reinshagen M, Adler G, Rieber A, et al. High prevalence of vertebral fractures in patients with Crohn's disease. Gut 2002; 51:654-658. This is the first study showing the clinical relevance of osteoporosis in Crohn's disease (CD) patients. The prevalence of vertebral fractures in CD is significantly increased compared to healthy subjects.
3. Celotti F, Bignamini A. Dietary calcium and mineral/vitamin supplementation: a controversial problem. J Int Med Res 1999; 27:1-14.
4. Welten DC, Kemper HC, Post GB, van Staveren WA. A meta-analysis of the effect of calcium intake on bone mass in young and middle aged females and males. J Nutr 1995; 125:2802-2813. Meta-analysis of 33 intervention studies showing that calcium supplementation of 1 g/day calcium in premenopausal women can prevent bone loss of 1% per year at all bone sites except the ulna.
5. Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ. Effect of calcium supplementation on bone loss in postmenopausal women. N Engl J Med 1993; 328:460-464. Randomized, placebo controlled study in 122 postmenopausal women showing that supplementation of 1 g/day calcium reduces loss of total body bone mineral density by 43%.
6. Massinger-Rapport BJ, Thacker HL. Prevention for the older woman. A practical guide to prevention and treatment of osteoporosis. Geriatrics 2002; 57:16-27.
7. Holick MF. Vitamin D and bone health. J Nutr 1996; 126:1159S-1164S.
8. Riggs BL, O'Fallon WM, Muhs J, O'Connor MK, Kumar R, Melton LJ 3rd. Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women. J Bone Miner Res 1998; 13:168-174.
9. Beresford SA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997; 349:458-461.
10. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332:1589-1593.
11. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288:58-66.
12. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288:321-333.
13. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282:637-645.
14. Muff R, Dambacher MA, Fischer JA. Formation of neutralizing antibodies during intranasal synthetic sarmon calcitonin treatment of postmenopausal osteoporosis. Osteoporos Int 1991; 1:72-75.
15. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in estabrished osteoporosis: a dose-response study. BMJ 1992; 305:556-561.
16. Ellerington MC, Hillard TC, Whitcroft SI, Marsh MS, Lees B, Banks LM, et al. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis. Calcif Tissue Int 1996; 59:6-11.
17. Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures study. PROOF Study Group. Am J Med 2000; 109:267-276.
18. Downs RW Jr, Bell NH, Ettinger MP, Walsh BW, Favus MJ, Mako B, et al. Comparison of alendronate and intranasal carcitonin for treatment of osteoporosis in postmenopausal women. J Clin Endocrinol Metab 2000; 85:1783-1788.
19. Arnala I, Saastamoinen J, Alhava EM. Salmon calcitonin in the prevention of bone loss at perimenopause. Bone 1996; 18:629-632.
20. Overgaard K. Effect of intranasal salmon calcitonin therapy on bone mass and bone turnover in early postmenopausal women: a dose-response study. Calcif Tissue Int 1994; 55:82-86.
21. Gennari C, Agnusdei D, Camporeale A. Use of calcitonin in the treatment of bone pain associated with osteoporosis. Calcif Tissue Int 1991; 49 (suppl 2):S9-S13.
22. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999; 25:97-106.
23. De Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335:1016-1021.
24. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322:1265-1271.
25. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323:73-79. In this 2 year, double blind, placebo controlled, multi-centre study in 429 women with postmenopausal osteoporosis and at least one vertebral compression the rate of new vertebral fractures was reduced by half in the etidronate treated patients. This study shows the evidence of treatment with etidronate in postmenopausal osteoporosis leading to an approval in many countries.
26. Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993; 95:557-567.
27. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333:1437-1443. This is the corresponding study to the etidronate study published by Watts et al.[25]. In this multi-centre study different doses of alendronate (5, 10 and 20 mg/day) were investigated in women with postmenopausal osteoporosis showing a 48% reduction in the proportion of women with new vertebral fractures. As mentioned above this study also was important for the approval of alendronate in this indication.
28. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention Trial Research Group. Lancet 1996; 348:1535-1541.
29. Thiebaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997; 103:298-307.
30. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346:653-661.
31. Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 2001; 86:5252-5255.
32. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339:292-299. The study shows that alendronate is not only beneficial in primary osteoporosis but also in steroid induced osteoporosis. Therefore this result may be parity transferable to patients with inflammatory bowel disease who are on steroids.
33. Haguenauer D, Welch V, Shea B, Tugwell P, Wells G. Fluoride for treating postmenopausal osteoporosis. Cochrane Database Syst Rev 2000; 4:CD002825.
34. Rubin CD, Pak CY, Adams-Huet B, Genant HK, Li J, Rao DS. Sustained-release sodium fluoride in the treatment of the elderly with established osteoporosis. Arch Intern Med 2001; 161:2325-2333.
35. von Tirpitz C, Klaus J, Steinkamp M, Hofbauer LC, Kratzer W, Mason R, et al. Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. Aliment Pharmacol Ther 2003; 17:807-817.
36. Meunier PJ, Sebert JL, Reginster JY, Briancon D, Appelboom T, Netter P, et al. Fluoride salts are no better at preventing new vertebral fractures than calcium - vitamin D in postmenopausal osteoporosis: the FAVOStudy. Osteoporos Int 1998; 8:4-12.
37. Pak CY, Sakhaee K, Piziak V, Peterson RD, Breslau NA, Boyd P, et al. Slow-release sodium fluoride in the management of postmenopausal osteoporosis. A randomized controlled trial. Ann Intern Med 1994; 120:625-632. Randomized study showing that 50 mg/day sustained release sodium fluoride can increase bone mineral density and reduces vertebral fracture rate without any additional risk for non-vertebral fractures.
38. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322:802-809. This study showed an increase of lumbar bone mineral density but also an increase of non-vertebral fractures in postmenopausal osteoporosis at the same time when treated with 75 mg/day sodium fluoride. This study is one of the main reasons why sodium fluoride is regarded critically as a treatment modality in postmenopausal osteoporosis.
39. Ringe JD, Rovati LC. Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates. Calcif Tissue Int 2001; 69:252-255.
40. Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 1997; 350:550-555.
41. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434-1441.
42. Srivastava SK, Weitzmann MN, Chaudhari LR, Namba N, Pacifici R. Estrogen decreases the responsiveness of osteoclast precursors to OPGL by down regulating OPGL induced JNK activity. J Bone Miner Res 1999; 14 (suppl 1):1178.
43. Akatsu T, Murakami T, Ono K, Nishikawa M, Tsuda E, Mochizuki SI, et al. Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. Bone 1998; 23:495-498.
44. Bekker PJ, Holloway D, Nakanishi A, Arrighi HM, Dunstan CR. Osteoprotegerin (OPG) has potent and sustained anti-resorptive activity in postmenopausal women. J Bone Miner Res 1999; 14 (suppl 1):1190.
45. Vasquez H, Mazure R, Gonzalez D, Flores D, Pedreira S, Niveloni S, et al. Risk of fractures in celiac disease patients: a cross-sectional, case-control study. Am J Gastroenterol 2000; 95:183-189.
46. Walters JR. Bone mineral density in coeliac disease. Gut 1994; 35:150-151.
47. Walters JR, Banks LM, Butcher GP, Fowler CR. Detection of low bone mineral density by dual energy X ray absorptiometry in unsuspected suboptimally treated coeliac disease. Gut 1995; 37:220-224.
48. Nuti R, Martini G, Valenti R, Giovani S, Salvadori S, Avanzati A. Prevalence of undiagnosed coeliac syndrome in osteoporotic women. J Intern Med 2001; 250:361-366.
49. Sategna-Guidetti C, Grosso SB, Grosso S, Mengozzi G, Aimo G, Zaccaria T, et al. The effects of 1-year gluten withdrawal on bone mass, bone metabolism and nutritional status in newly-diagnosed adult coeliac disease patients. Aliment Pharmacol Ther 2000; 14:35-43. Study underlines the importance of strict gluten withdrawal with regard to the improvement of bone mineral density.
50. Mustalahti K, Collin P, Sievanen H, Salmi J, Maki M. Osteopenia in patients with clinically silent coeliac disease warrants screening. Lancet 1999; 354:744-745.
51. Kemppainen T, Kroger H, Janatuinen E, Arnala I, Lamberg-Allardt C, Karkkainen M, et al. Bone recovery after a gluten-free diet: a 5-year follow-up study. Bone 1999; 25:355-360.
52. Szathmari M, Tulassay T, Arato A, Bodanszky H, Szabo A, Tulassay Z. Bone mineral content and density in asymptomatic children with coeliac disease on a gluten-free diet. Eur J Gastroenterol Hepatol 2001; 13:419-424.
53. Valdimarsson T, Toss G, Ross I, Lofman O, Strom M. Bone mineral density in coeliac disease. Scand J Gastroenterol 1994; 29:457-461.
54. Scott EM, Gaywood I, Scott BB. Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology. Gut 2000; 46 (suppl 1):1-8.
55. Dorst AJ, Ringe JD. Severe osteomalacia in endemic sprue. An important differential diagnosis in osteoporosis. Fortschr Med 1998; 116:42-45.
56. Mautalen C, Gonzalez D, Mazure R, Vazquez H, Lorenzetti MP, Maurino E, et al. Effect of treatment on bone mass, mineral metabolism, and body composition in untreated celiac disease patients. Am J Gastroenterol 1997; 92:313-318.
57. Lemieux B, Boivin M, Brossard JH, Lepage R, Picard D, Rousseau L, et al. Normal parathyroid function with decreased bone mineral density in treated celiac disease. Can J Gastroenterol 2001; 15:302-307.
58. Fornari MC, Pedreira S, Niveloni S, Gonzalez D, Diez RA, Vazquez H, et al. Pre- and post-treatment serum levels of cytokines IL-1beta, IL-6, and IL-1 receptor antagonist in celiac disease. Are they related to the associated osteopenia? Am J Gastroenterol 1998; 93:413-418.
59. Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut 1995; 37:71-76.
60. Clements D, Compston JE, Evans WD, Rhodes J. Hormone replacement therapy prevents bone loss in patients with inflammatory bowel disease. Gut 1993; 34:1543-1546.
61. Bernstein CN, Seeger LL, Anton PA, Artinian L Gefrey S, Goodman W, et al. A randomized, placebo-controlled trial of calcium supplementation for decreased bone density in corticosteroid-using patients with inflammatory bowel disease: a pilot study. Ailment Pharmacol Ther 1996; 10:777-786. Randomized, placebo controlled but small study showing a positive effect of calcium/vitamin D supplementation on bone mineral density in Crohn's disease patients.
62. Vogelsang H, Ferenci P, Resch H, Kiss A, Gangl A. Prevention of bone mineral loss in patients with Crohn's disease by long-term oral vitamin D supplementation. Eur J Gastroenterol Hepatol 1995; 7:609-614.
63. Abitbol V, Mary JY, Roux C, Soulé JC, Belaiche J, Dupas JL, et al. Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride. Aliment Pharmacol Ther 2002; 16:919-927.
64. v. Tirpitz C, Klaus J, Brückel J, Rieber A, Scholer A, Adler G, et al. Increase of bone mineral density with sodium fluoride in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2000; 11:19-24.
65. Haderslev KV, Tjellesen L, Sorensen HA, Staun M. Alendronate increases lumbar spine bone mineral density in patients with Crohn's disease. Gastroenterology 2000; 119:639-646. First published placebo controlled study using a bisphosphonate in 31 patients with Crohn's disease and reduced bone mineral density showing a significant benefit compared to calcium/vitamin D supplementation alone.
66. Robinson RJ, Krzywicki T, Almond L, Al-Azzawi F, Abrams K, Iqbal SJ, et al. Effect of a low-impact exercise program on bone mineral density in Crohn's disease: a randomized controlled trial. Gastroenterology 1998; 115:36-41.
67. Zittel TT, Zeeb B, Maier GW, Kaiser GW, Zwirner M, Liebich H, et al. High prevalence of bone disorders after gastrectomy. Am J Surg 1997; 174:431-438.
68. Davies M, Heys SE, Selby PL, Berry JL, Mawer EB. Increased catabolism of 25-hydroxyvitamin D in patients with partial gastrectomy and elevated 1,25-dihydroxyvitamin D levels. Implications for metabolic bone disease. J Clin Endocrinol Metab 1997; 82:209-212.
69. Tovey FI, Hall ML, Ell PJ, Hobsley M. A review of postgastrectomy bone disease. J Gastroenterol Hepatol 1992; 7:639-645.
70. Bisballe S, Eriksen EF, Melsen F, Mosekilde L, Sorensen OH, Hessov I. Osteopenia and osteomalacia after gastrectomy: interrelations between biochemical markers of bone remodelling, vitamin D metabolites, and bone histomorphometry. Gut 1991; 32:1303-1307.
71. Alhava EM, Aukee S, Karjalainen P, Kettunen K, Juuti M. The influence of calcium and calcium + vitamin D2 treatment on bone mineral after partial gastrectomy. Scand J Gastroenterol 1975; 10:689-693.
72. Tovey FI, Hall ML, Ell PJ, Hobsley M. Postgastrectomy osteoporosis. Br J Surg 1991; 78:1335-1377.
73. Maier GW, Kreis ME, Zittel TT, Becker HD. Calcium regulation and bone mass loss after 74 total gastrectomy in pigs. Ann Surg 1997; 225:181-192.
74. Tovey FI, Hall ML, Ell PJ, Hobsley M. Cyclical etidronate therapy and postgastrectomy osteoporosis. Br J Surg 1994; 81:1168-1169.
75. Moran CE, Sosa EG, Martinez SM, Geldern P, Messina D, Russo A, et al. Bone mineral density in patients with pancreatic insufficiency and steatorrhea. Am J Gastroenterol 1997; 92:867-871.
76. Haaber AB, Rosenfalck AM, Hansen B, Hilsted J, Larsen S. Bone mineral metabolism, bone mineral density, and body composition in patients with chronic pancreatitis and pancreatic exocrine insufficiency. Int J Pancreatol 2000; 27:21-27.